title: Romidepsin used as monotherapy in sequence with allogeneic stem cell transplant in a patient with peripheral T-cell lymphoma.
abstract: Despite advances in the field, a clear treatment algorithm for most peripheral T-cell lymphoma (PTCL) subtypes remains to be defined. Generating reliable randomized data for this type of pathology remains a challenge because of the relative rarity of the disease and the heterogeneity of subtypes. Newer agents, such as the class-I selective histone deacetylase inhibitor romidepsin, have demonstrated efficacy and manageable toxicity in the relapsed and refractory setting. Whether novel agents should be used in conjunction with more conventional cytotoxic therapies or in sequence with a transplant strategy is unknown at this time. Here we report the successful use of romidepsin monotherapy as a bridge to allogeneic stem cell transplantation in a patient who had previously relapsed after several lines of conventional cytotoxic therapy for PTCL. Romidepsin provided the patient with sufficient disease control to proceed to transplantation while remaining in complete remission.
authors.affiliation: Dr. Léon-Richard Oncology Centre, 37 Providence Street, Moncton, NB, Canada E1C 8X3.
authors.forename: Nicholas
authors.identifier: 0000-0002-4908-6824
authors.initials: N
authors.lastname: Finn
authors.affiliation: CHU de Québec, Hôpital Enfant-Jésus, 1401 18e Rue, Quebec, QC, Canada G1J 1Z4.
authors.forename: Jean-Francois
authors.identifier: 0000-0002-9645-2815
authors.initials: JF
authors.lastname: Larouche
references.citation: Blood. 2011 Jun 2;117(22):5827-34
references.pmid: 21355097
references.citation: Curr Treat Options Oncol. 2013 Jun;14(2):212-23
references.pmid: 23568456
references.citation: Semin Hematol. 2014 Jan;51(1):67-72
references.pmid: 24468318
references.citation: J Clin Oncol. 2012 Feb 20;30(6):631-6
references.pmid: 22271479
references.citation: Adv Hematol. 2010;2010:320624
references.pmid: 21253465
references.citation: J Hematol Oncol. 2014 Jan 23;7:11
references.pmid: 24456586